Holen Sie sich die Stockscreener-App
0.5874
2.73%
0.0156
Schlusskurs vom Vortag:
$0.5718
Offen:
$0.57
24-Stunden-Volumen:
25,457
Relative Volume:
0.23
Marktkapitalisierung:
$5.55M
Einnahmen:
$34.07M
Nettoeinkommen (Verlust:
$-20.13M
KGV:
-0.0455
EPS:
-12.92
Netto-Cashflow:
$-24.90M
1W Leistung:
-8.08%
1M Leistung:
-18.42%
6M Leistung:
-37.25%
1J Leistung:
-42.97%
1-Tages-Spanne:
$0.5526
$0.5874
1-Wochen-Bereich:
$0.536
$0.63
52-Wochen-Spanne:
$0.536
$2.22
Biofrontera Inc Stock (BFRI) Company Profile
Firmenname
Biofrontera Inc
Sektor
Telefon
781-245-1325
Adresse
120 PRESIDENTIAL WAY,, WOBURN
Vergleichen Sie BFRI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.5874 | 6.04M | 34.07M | -20.13M | -24.90M | -12.92 |
|
HLN
Haleon Plc Adr
|
11.14 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
171.19 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.86 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.97 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.27 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Biofrontera Inc Aktie (BFRI) Neueste Nachrichten
Biofrontera stock hits 52-week low at $0.58 amid market challenges By Investing.com - Investing.com South Africa
Biofrontera stock hits 52-week low at $0.58 amid market challenges - Investing.com India
Biofrontera AG Faces Financial Uncertainty Amid Biofrontera Inc. Payment Issues - TipRanks
Biofrontera Receives Nasdaq Non-Compliance Notice - TipRanks
Roth Capital Decreases Earnings Estimates for Biofrontera - Defense World
Q2 Earnings Forecast for Biofrontera Issued By Roth Capital - Defense World
Biofrontera Inc. (NASDAQ:BFRI) Q1 2025 Earnings Call Transcript - Insider Monkey
Biofrontera (NASDAQ:BFRI) Price Target Lowered to $2.75 at Benchmark - Defense World
Biofrontera, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Benchmark cuts Biofrontera stock target to $2.75, keeps Buy rating By Investing.com - Investing.com Nigeria
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com - FinancialContent
Biofrontera (BFRI) Sees Price Target Reduction by Benchmark | BF - GuruFocus
Benchmark cuts Biofrontera stock target to $2.75, keeps Buy rating - Investing.com Australia
Biofrontera (BFRI) Target Price Trimmed After Lower Revenue Perf - GuruFocus
Biofrontera Inc. price target lowered to $2.75 from $7 at Benchmark - TipRanks
Biofrontera signals 2025 record revenue ambitions with new Ameluz patent and cost controls - MSN
Biofrontera Inc. (BFRI) Reports 9% Revenue Growth in Q1 2025 - GuruFocus
Earnings call transcript: Biofrontera Q1 2025 sees revenue rise, stock dips - Investing.com Nigeria
Earnings call transcript: Biofrontera Q1 2025 sees revenue rise, stock dips By Investing.com - Investing.com South Africa
Transcript : Biofrontera Inc., Q1 2025 Earnings Call, May 16, 2025 - marketscreener.com
BFRI Increases Q1 Revenue and Expands Market Presence | BFRI Sto - GuruFocus
Biofrontera extends Ameluz patent to 2043 for acne treatment By Investing.com - Investing.com Nigeria
Biofrontera Inc. reports Q1 EPS (47c) vs. ($2.88) last year - TipRanks
Biofrontera Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Biofrontera Inc. (BFRI) Sees Encouraging Revenue Growth in Q1 | - GuruFocus
Biofrontera Inc. (BFRI) Sees Encouraging Revenue Growth in Q1 | BFRI Stock News - GuruFocus
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update - The Manila Times
Biofrontera Inc. reports Q1 EPS (47c) vs. (71c) last year - TipRanks
Biofrontera (BFRI) Achieves Patent Approval and Advances Clinica - GuruFocus
Biofrontera Announces New Patent Protection On Ameluz Until 2043 - marketscreener.com
Biofrontera (BFRI) Achieves Patent Approval and Advances Clinical Trials | BFRI Stock News - GuruFocus
Biofrontera's Revised Ameluz Formulation Receives US Patent Approval - marketscreener.com
Biofrontera extends Ameluz patent to 2043 for acne treatment - Investing.com
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris - The Manila Times
Biofrontera Inc. announces patent protection on Ameluz until 2043 - TipRanks
Biofrontera Inc. faces Nasdaq delisting over share price By Investing.com - Investing.com Nigeria
Biofrontera Inc. faces Nasdaq delisting over share price - Investing.com Australia
Biofrontera Faces Nasdaq Non-Compliance Notice - TipRanks
Biofrontera (BFRI) to Release Earnings on Thursday - Defense World
Dermatology Leader Biofrontera Announces First Quarter 2025 Earnings Date: Key Details Inside - Stock Titan
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025 - ACCESS Newswire
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis - GlobeNewswire
Finanzdaten der Biofrontera Inc-Aktie (BFRI)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.28%
2.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):